

SCHEME DETAILS



Inception Date
08-Nov-2021



Category
Sectoral/ Thematic



Benchmark Index
Nifty Healthcare TRI



Monthly AAUM **AUM**
₹ 140.13 Crores ₹ 143.28 Crores



Minimum Application Amount:
₹ 5,000/- & in multiples of ₹ 1/- thereafter



Load Structure

Entry Load: Nil

Exit Load: · 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units; · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.



Fund Manager



Mr. Rohan Korde
(Since 08-Nov-21)
Total Experience:
19 years



Mr. Dhimant Shah
(Since 01-Dec-22)
Total Experience:
26 years

FUND HIGHLIGHTS

- ▶ The fund shall have allocations across healthcare ecosystem like Domestic Pharma, Global Pharma
- ▶ The fund shall intend to capitalize on changing trends that are reshaping Global Pharma & Healthcare industry.
- ▶ The sector has potentially lower volatility
- ▶ Suitable for investors who have investment horizon of 4-5 years & want to be part of Indian Healthcare Growth Story

OUTLOOK - EQUITY

Long-term outlook remains intact:

- ▶ Going forward while all eyes are on the General Elections, all the three elements of the capex cycle (Housing, Corporate Capex & Govt Capex) are now firing and hence the potential global slowdown should have limited impact on India. A combination of a strong pent-up demand for housing, above average affordability and 12-year low unsold inventory should drive a multi-year virtuous housing cycle. Ditto for corporate capex with all time low D/E ratio for Indian corporate, along with a decade high capacity utilisation level and well capitalised banking system should drive corporate capex. Govt Capex could slowdown but private capex pick-up should more than offset.
- ▶ Unlike every year, the budget would be a Vote on Account in this financial year. However, considering election year, one cannot rule out a populist measures being announced in the budget. During 2019-20, the first interim budget of the incumbent government saw various measures being implemented like PM Kisan Yojana – transferring Rs.6000 per annum x ~12 crore farmers entailing an outlay of Rs.75,000 crore per annum. These sort of measures are expected to not only provide spending impetus at the lower strata of the society but is also expected to reinforce the positioning of the incumbent Government with a strong majority.

SUB - SECTOR CLASSIFICATION


Sector	Dec-23	Nov-23	Oct-23
Healthcare	93.41%	93.87%	94.25%
Others*	4.34%	4.75%	4.45%

The portfolio of the scheme is subject to changes within the provisions of the Scheme Information document of the scheme. Please refer to the SID for investment pattern, strategy, risk factors & the asset allocation. Please refer to the factsheet for more details. *Others include Chemicals, Financial Services, Realty, FMCG & Diversified.

PORTFOLIO TRENDS

	Dec-23	Nov-23	Oct-23
Average P/E	103.53	50.71	46.68
Average P/B	6.95	6.65	5.92
No. of stocks:	35	36	36
% of top 5 holdings	35.94	35.99	38.36
% of top 10 holdings	59.19	59.60	60.52


MARKET CAP TRENDS



PORTFOLIO TOP HOLDINGS

Name of Instrument	% to NAV
Sun Pharmaceutical Industries Ltd.	13.58%
Dr. Reddy's Laboratories Ltd.	5.92%
Max Healthcare Institute Ltd.	5.89%
Alkem Laboratories Ltd.	5.38%
Suven Pharmaceuticals Ltd.	5.16%
Mankind Pharma Ltd.	4.96%
Aurobindo Pharma Ltd.	4.92%
Lupin Ltd.	4.58%
Cipla Ltd.	4.56%
Apollo Hospitals Enterprise Ltd.	4.23%

ASSET ALLOCATION - DECEMBER 2023




Equities : 97.76%
Others : 2.24%

Consult your financial advisor or Call toll-free No: 1800-266-9603 Mail: mfasst@itiorg.com Website: www.itiamc.com

This product is suitable for investors who are seeking*:

- Capital appreciation over long term
- Investments in equity and equity related securities of companies engaged in Pharma and Healthcare.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.



Riskometer as on 29th December 2023

DISCLAIMER: The investment strategy of the scheme may change from time to time and shall be in accordance with the strategy as mentioned in the Scheme Information document of the scheme. The views contained herein are not to be taken as an advice or recommendation to buy or sell any particular stock. The above information must be read along with the scheme features & riskometer for better understanding of the product. This should not be construed as an investment advice. Investors may consult their Mutual Fund Distributor for other details. It should be noted that value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements. **Past performance may or may not be sustained in future.**

Distributed by: